Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study

C Bakkers; F N van Erning; K P Rovers; S W Nienhuijs; J W Burger; V E Lemmens; A G Aalbers; N F Kok; D Boerma; A R Brandt; P H Hemmer; W M van Grevenstein; P R de Reuver; P J Tanis; J B Tuynman; I H de Hingh

doi:10.1016/j.ejso.2020.04.018

Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study

C Bakkers^*
, F N van Erning
, K P Rovers
, S W Nienhuijs
, J W Burger
, V E Lemmens
, A G Aalbers
, N F Kok
, D Boerma
, A R Brandt
, P H Hemmer
, W M van Grevenstein
, P R de Reuver
, P J Tanis
, J B Tuynman
, I H de Hingh

^*Corresponding author for this work

Catharina Cancer Institute
Netherlands Comprehensive Cancer Organization (IKNL)
Netherlands Cancer Institute
St. Antonius Hospital
Erasmus MC Cancer Institute
University Medical Centre Groningen
University Medical Centre Utrecht
Radboud University Medical Center
Amsterdam UMC
Maastricht University

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

6 Downloads (Pure)

Abstract

OBJECTIVES:

In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.

METHODS:

This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. They were retrieved from the Netherlands Cancer Registry. Main outcome was overall survival (OS). The effect of the intraperitoneal drug on OS was investigated using multivariable Cox regression analysis.

RESULTS:

In total, 297 patients treated between 2014 and 2017 were included. Among them, 177 (59.6%) received MMC and 120 (40.4%) received oxaliplatin. Only primary tumor location was different between the two groups: more left-sided colon in the Oxaliplatin group (47.5% vs. 33.3%, respectively, p=0.048). The 1-, 2- and 3-year OS were 84.6% vs. 85.8%, 61.6% vs. 63.9% and 44.7% vs. 53.5% in patients treated with MMC and oxaliplatin, respectively. Median OS was 30.7 months in the MMC group vs. 46.6 months in the oxaliplatin group (p=0.181). In multivariable analysis, no influence of intraperitoneal drug on survival was observed (adjusted HR 0.77 [0.53-1.13]).

CONCLUSIONS:

Long-term survival between patients treated with either MMC or oxaliplatin during CRS-HIPEC was not significantly different.

Original language	English
Pages (from-to)	1902-1907
Number of pages	6
Journal	European Journal of Surgical Oncology
Volume	46
Issue number	10
DOIs	https://doi.org/10.1016/j.ejso.2020.04.018
Publication status	Published - Oct 2020
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC NIHES-02-65-01

Access to Document

10.1016/j.ejso.2020.04.018

Repub_131311.pdfFinal published version, 652 KBLicence: Article 25fa Dutch Copyright Act

http://hdl.handle.net/1765/131311

Cite this

Bakkers, C., van Erning, F. N., Rovers, K. P., Nienhuijs, S. W., Burger, J. W., Lemmens, V. E., Aalbers, A. G., Kok, N. F., Boerma, D., Brandt, A. R., Hemmer, P. H., van Grevenstein, W. M., de Reuver, P. R., Tanis, P. J., Tuynman, J. B., & de Hingh, I. H. (2020). Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. European Journal of Surgical Oncology, 46(10), 1902-1907. https://doi.org/10.1016/j.ejso.2020.04.018

@article{ffb1a2fd69204b538fdd99fc0fbcbd10,

title = "Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study",

abstract = "OBJECTIVES: In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.METHODS: This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. They were retrieved from the Netherlands Cancer Registry. Main outcome was overall survival (OS). The effect of the intraperitoneal drug on OS was investigated using multivariable Cox regression analysis.RESULTS: In total, 297 patients treated between 2014 and 2017 were included. Among them, 177 (59.6\%) received MMC and 120 (40.4\%) received oxaliplatin. Only primary tumor location was different between the two groups: more left-sided colon in the Oxaliplatin group (47.5\% vs. 33.3\%, respectively, p=0.048). The 1-, 2- and 3-year OS were 84.6\% vs. 85.8\%, 61.6\% vs. 63.9\% and 44.7\% vs. 53.5\% in patients treated with MMC and oxaliplatin, respectively. Median OS was 30.7 months in the MMC group vs. 46.6 months in the oxaliplatin group (p=0.181). In multivariable analysis, no influence of intraperitoneal drug on survival was observed (adjusted HR 0.77 [0.53-1.13]).CONCLUSIONS: Long-term survival between patients treated with either MMC or oxaliplatin during CRS-HIPEC was not significantly different.",

author = "C Bakkers and \{van Erning\}, \{F N\} and Rovers, \{K P\} and Nienhuijs, \{S W\} and Burger, \{J W\} and Lemmens, \{V E\} and Aalbers, \{A G\} and Kok, \{N F\} and D Boerma and Brandt, \{A R\} and Hemmer, \{P H\} and \{van Grevenstein\}, \{W M\} and \{de Reuver\}, \{P R\} and Tanis, \{P J\} and Tuynman, \{J B\} and \{de Hingh\}, \{I H\}",

year = "2020",

month = oct,

doi = "10.1016/j.ejso.2020.04.018",

language = "English",

volume = "46",

pages = "1902--1907",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

number = "10",

}

Bakkers, C, van Erning, FN, Rovers, KP, Nienhuijs, SW, Burger, JW , Lemmens, VE, Aalbers, AG, Kok, NF, Boerma, D, Brandt, AR, Hemmer, PH, van Grevenstein, WM, de Reuver, PR, Tanis, PJ, Tuynman, JB & de Hingh, IH 2020, 'Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study', European Journal of Surgical Oncology, vol. 46, no. 10, pp. 1902-1907. https://doi.org/10.1016/j.ejso.2020.04.018

Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. / Bakkers, C; van Erning, F N; Rovers, K P et al.
In: European Journal of Surgical Oncology, Vol. 46, No. 10, 10.2020, p. 1902-1907.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases

T2 - A nationwide comparative study

AU - Bakkers, C

AU - van Erning, F N

AU - Rovers, K P

AU - Nienhuijs, S W

AU - Burger, J W

AU - Lemmens, V E

AU - Aalbers, A G

AU - Kok, N F

AU - Boerma, D

AU - Brandt, A R

AU - Hemmer, P H

AU - van Grevenstein, W M

AU - de Reuver, P R

AU - Tanis, P J

AU - Tuynman, J B

AU - de Hingh, I H

PY - 2020/10

Y1 - 2020/10

N2 - OBJECTIVES: In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.METHODS: This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. They were retrieved from the Netherlands Cancer Registry. Main outcome was overall survival (OS). The effect of the intraperitoneal drug on OS was investigated using multivariable Cox regression analysis.RESULTS: In total, 297 patients treated between 2014 and 2017 were included. Among them, 177 (59.6%) received MMC and 120 (40.4%) received oxaliplatin. Only primary tumor location was different between the two groups: more left-sided colon in the Oxaliplatin group (47.5% vs. 33.3%, respectively, p=0.048). The 1-, 2- and 3-year OS were 84.6% vs. 85.8%, 61.6% vs. 63.9% and 44.7% vs. 53.5% in patients treated with MMC and oxaliplatin, respectively. Median OS was 30.7 months in the MMC group vs. 46.6 months in the oxaliplatin group (p=0.181). In multivariable analysis, no influence of intraperitoneal drug on survival was observed (adjusted HR 0.77 [0.53-1.13]).CONCLUSIONS: Long-term survival between patients treated with either MMC or oxaliplatin during CRS-HIPEC was not significantly different.

AB - OBJECTIVES: In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.METHODS: This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. They were retrieved from the Netherlands Cancer Registry. Main outcome was overall survival (OS). The effect of the intraperitoneal drug on OS was investigated using multivariable Cox regression analysis.RESULTS: In total, 297 patients treated between 2014 and 2017 were included. Among them, 177 (59.6%) received MMC and 120 (40.4%) received oxaliplatin. Only primary tumor location was different between the two groups: more left-sided colon in the Oxaliplatin group (47.5% vs. 33.3%, respectively, p=0.048). The 1-, 2- and 3-year OS were 84.6% vs. 85.8%, 61.6% vs. 63.9% and 44.7% vs. 53.5% in patients treated with MMC and oxaliplatin, respectively. Median OS was 30.7 months in the MMC group vs. 46.6 months in the oxaliplatin group (p=0.181). In multivariable analysis, no influence of intraperitoneal drug on survival was observed (adjusted HR 0.77 [0.53-1.13]).CONCLUSIONS: Long-term survival between patients treated with either MMC or oxaliplatin during CRS-HIPEC was not significantly different.

U2 - 10.1016/j.ejso.2020.04.018

DO - 10.1016/j.ejso.2020.04.018

M3 - Article

C2 - 32340819

SN - 0748-7983

VL - 46

SP - 1902

EP - 1907

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 10

ER -

Bakkers C, van Erning FN, Rovers KP, Nienhuijs SW, Burger JW , Lemmens VE et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. European Journal of Surgical Oncology. 2020 Oct;46(10):1902-1907. doi: 10.1016/j.ejso.2020.04.018

Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study

Abstract

Bibliographical note

UN SDGs

Research programs

Access to Document

Fingerprint

Cite this